Tailoring the treatment of Parkinson’s disease (PD) for different patient subgroups represents a major step forward in the management of patients with PD, but new efforts are needed to move beyond subgroups to individualized treatment approaches.
At the MDS 2021 virtual congress, Dr Connie Marras of the University of Toronto, Canada, noted that current treatment of PD is already tailored to different subgroups based on clinical features. These features include age at onset and the presence of certain motor and non-motor symptoms.